BioSpace News Archive

Drug Development

FDA Adcomm Backs AstraZeneca’s Asthma Drug for Adults, but not Children

The FDA deemed AstraZeneca’s PT027 to have a favorable risk-benefit profile for treating asthma in patients aged 18 or older but was less keen on supporting the drug in younger populations.

November 9, 2022
·
3 min read
·
Tristan Manalac
Drug Development

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS

With a fresh $18 million in the bank, NRG Therapeutics is ready to put its novel mitochondrial approach to the test for devastating neurodegenerative disorders—Parkinson’s and ALS.

November 9, 2022
·
2 min read
·
Kate Goodwin
Business

Adaptimmune Slashes 25% of Headcount Despite Improved Data for T-Cell Candidate - Updated

Adaptimmune has had a manic Tuesday, touting improved efficacy numbers for its T-cell candidate while also dealing with economic repercussions of its terminated partnership with GSK.

November 9, 2022
·
2 min read
·
Tristan Manalac
Deals

Clovis Axes 115 Employees, Warns of Potential Bankruptcy

Bankruptcy might be looming for embattled Clovis Oncology, the company warned Wednesday in a 10-Q filing. Clovis also revealed it has taken action to reduce its workforce by 115 employees.

November 9, 2022
·
2 min read
·
Heather McKenzie
Drug Development

Oncolytics Presents Promising Pancreatic Cancer Data at SITC

Oncolytics Biotech released data Thursday from a Phase I/II study in pancreatic ductal adenocarcinoma that support plans to advance the program into Phase III.

November 9, 2022
·
3 min read
·
Rosemary Scott
FDA

Regeneron Carves Out Bigger Slice of NSCLC Market with New Approval

The FDA greenlit Libtayo plus chemotherapy to treat patients with advanced NSCLC irrespective of EGFR, ALK or ROS1 aberrations. It is the drug’s second approval in this space.

November 9, 2022
·
2 min read
·
Heather McKenzie
Drug Development

Ipsen to File sNDA for Pancreatic Cancer Drug Following Positive Phase III Results

Ipsen will seek a new approval for Onivyde as a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) after posting positive Phase III progression survival data.

November 9, 2022
·
2 min read
·
Alex Keown
Zenas BioPharma Rakes in $118M to Advance Autoimmune Program - Updated

Zenas BioPharma closed on a Series B financing round worth $118 million, which it will use to advance its autoimmune candidate obexelimab into a global Phase III trial later this year.

November 9, 2022
·
2 min read
·
Mark Terry
Career Advice

How to Know if Clinical Research is Right for You

At the foundation of every clinical trial are the professionals who ensure its successful execution. Read on to find out more about how to know if clinical research is right for you.

November 9, 2022
·
4 min read
·
Franklin Carpenter
Sponsored: Are You Looking for a Long-Term Partnership for Your Next OEM Project? Trust Our Expertise

Discover how Eppendorf OEM worked with the market leader in laboratory automation to develop a win-win business model and 25-year partnership.

November 9, 2022
·
1 min read
·
Sponsored Content